<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04647357</url>
  </required_header>
  <id_info>
    <org_study_id>LS-SCLC-MT-IIT-SHR1316</org_study_id>
    <nct_id>NCT04647357</nct_id>
  </id_info>
  <brief_title>A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer</brief_title>
  <official_title>A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer Without Progression After First Line Concurrent Chemoradiotherapy Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SHR-1316 as Maintenance therapy for limited stage small cell lung cancer without progression&#xD;
      after first line platinum based concurrent chemoradiotherapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 27, 2020</start_date>
  <completion_date type="Anticipated">December 27, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 27, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>progression-free survival</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Limited-stage Small Cell Lung Cancer, LS-SCLC</condition>
  <arm_group>
    <arm_group_label>SHR-1316</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1316</intervention_name>
    <description>Anti-PD-L1 antibodyï¼ŒMaintenance therapy, The drug was administered every three weeks</description>
    <arm_group_label>SHR-1316</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The age is 18-75 years old (including both ends), regardless of gender;&#xD;
&#xD;
          2. Histologically confirmed limited stage small cell lung cancer ;&#xD;
&#xD;
          3. ECOG PS 0 ~ 1;&#xD;
&#xD;
          4. Patients received at least 2 cycles of platinum based chemotherapy and radiotherapy,&#xD;
             and completed within 1 to 42 days before the first medication.&#xD;
&#xD;
          5. The last chemotherapy must be finished before or at the same time of radiotherapy.&#xD;
&#xD;
          6. The disease did not progress after concurrent chemoradiotherapy;&#xD;
&#xD;
          7. The expected survival time was more than 3 months;&#xD;
&#xD;
          8. Pulmonary function: FEV1 &gt; 70%;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subjects volunteered to participate in the study, signed the informed consent&#xD;
             form, had good compliance and cooperated with the follow-up.&#xD;
&#xD;
          2. Mixed SCLC or NSCLC confirmed by histology;&#xD;
&#xD;
          3. Locally advanced small cell lung cancer receiving sequential chemoradiotherapy;&#xD;
&#xD;
          4. Have received anti-tumor therapy of systemic immune checkpoint inhibitors for SCLC;&#xD;
&#xD;
          5. Extensive SCLC;&#xD;
&#xD;
          6. Operable SCLC (clinical stage T1-2N0, except for those who are contraindicated or&#xD;
             refuse surgery);&#xD;
&#xD;
          7. Interstitial pneumonia&#xD;
&#xD;
          8. History of active, known or suspected autoimmune diseases and autoimmune diseases,&#xD;
             including but not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.&#xD;
&#xD;
          9. HIV, active Hepatitis B or Hepatitis C infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaorong Dong, PhD</last_name>
    <phone>027-85872859</phone>
    <email>xiaorongdong@hust.edu.cn</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 27, 2020</study_first_submitted>
  <study_first_submitted_qc>November 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2020</study_first_posted>
  <last_update_submitted>November 27, 2020</last_update_submitted>
  <last_update_submitted_qc>November 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>Xiaorong Dong</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

